Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, the therapeutic generic equivalent to NOXAFIL® (posaconazole) Delayed-Release Tablets, 100 mg approved by the U.S. Food and Drug Administration (USFDA).

The NOXAFIL® brand and generic had U.S. sales of approximately $140.8 million MAT for the most recent twelve months ending in February 2022 according to IQVIA*.

Dr. Reddy's Posaconazole Delayed-Release Tablets are available in 100 mg strength in bottle count sizes of 60.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4291.45 as compared to the previous close of Rs. 4211.45. The total number of shares traded during the day was 12884 in over 2425 trades.

The stock hit an intraday high of Rs. 4336.25 and intraday low of 4213.55. The net turnover during the day was Rs. 55286821.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY USFDA Approval Posaconazole DelayedRelease Tablets